Amgen has filed for approval from the European Union’s European Medicines Agency (EMA) for ABP 980, its biosimilar of the breast cancer treatment trastuzumab (Roche’s Herceptin), according to a presentation by Amgen’s executive vice president and chief financial officer David Meline at the Cowen and Company 37th Annual Health Care Conference on March 8, 2017. The report also suggests that Amgen is likely to file for its trastuzumab biosimilar’s approval in the United States, but the timing for that event is uncertain.
A biosimilar for trastuzumab has not yet been approved by the EMA or the FDA. The EMA’s website indicates that the agency is currently assessing 3 trastuzumab biosimilars, with Mylan/Biocon’s trastuzumab being the first under consideration for approval in 2017. Asia is already marketing a trastuzumab biosimilar and a recent court decision in New Delhi, India, allowed the marketing of Mylan/Biocon’s biosimilar of trastuzumab in that country.
Launch of a biosimilar of trastuzumab in Europe is expected to occur before a similar approval in the United States, but indications are growing stronger that Mylan’s trastuzumab biosimilar may be approved in September 2017 based on the recent announcement that Mylan entered a global settlement with Genentech and Hoffman-La Roche on a patent for trastuzumab. The agreement will provide Mylan with global licenses for its trastuzumab biosimilar, which allows Mylan and partner Biocon to commercialize the drug around the world with the exception of Japan, Brazil, and Mexico. The agreement also ensures that the US market will see the first biosimilar to trastuzumab, once Mylan’s biologics license application—filed in collaboration with Biocon—is approved by the FDA.
The Biosimilar User Fee Act for trastuzumab is September 3, 2017.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.